Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMPAHCT-FUL long-term extension of inhaled AV-101 in pulmonary arterial hypertension
NL-OMON53603Phase 3Not yet recruiting
- Sponsor
- Aerovate Therapeutics, Inc
- Start
- Nov 2023
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of 4-chlorokynurenine in pulmonary arterial hypertension (PAH), sponsored by Aerovate Therapeutics, Inc. Primary endpoint: Safety and tolerability of AV-101. Planned start Nov 2023; status: not yet recruiting.
02
Drugs
4-chlorokynurenine
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NL-OMON53603.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53603.